Literature DB >> 8174123

Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin.

T Saga1, J N Weinstein, J M Jeong, T Heya, J T Lee, N Le, C H Paik, C Sung, R D Neumann.   

Abstract

Two-step monoclonal antibody tumor targeting using an avidin-biotin system has unique characteristics because of the high-affinity binding (10(15) M-1) and the lower molecular weight ligands (avidin, streptavidin, or biotin) used as carriers of radioisotopes, toxins, or drugs. The distribution of radiolabeled streptavidin in a two-step targeting strategy was investigated in lung metastases of line 10 carcinoma in guinea pigs. The microdistribution of administered D3 monoclonal antibody and 125I-labeled streptavidin in metastatic nodules was examined by immunohistochemistry and autoradiography, and the uptake was quantitated. With monoclonal antibody pretargeting, streptavidin was found mainly at the periphery of metastatic nodules 1.5 h after injection; it had penetrated deeper at 4 h and was approaching homogeneity in many of the tumor nodules at 24 h. These results indicate that streptavidin can penetrate into metastatic nodules more rapidly than can the antibody. The concentration of streptavidin in metastatic nodules 4 h after injection was 5.6 times higher for the pretargeted group than for the nonpretargeted group, and the pretargeting index was 4.7. Although the absolute uptake of streptavidin had decreased between 4 and 24 h, the metastasis:blood ratio had increased from 1.2 to 2.4. When compared with the animals injected with 125I-labeled D3 antibody alone, the pretargeted group achieved higher tumor:blood and tumor:lung ratios and a higher localization index at early times after injection of the radiolabeled species.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8174123

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  In vivo assembly of nanoparticle components to improve targeted cancer imaging.

Authors:  Steven D Perrault; Warren C W Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

Authors:  David M Goldenberg; Chien-Hsing Chang; Robert M Sharkey; Edmund A Rossi; Habibe Karacay; William McBride; Hans J Hansen; Jean-Francois Chatal; Jacques Barbet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-06       Impact factor: 9.236

Review 3.  Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals.

Authors:  Hisataka Kobayashi; Michelle R Longmire; Mikako Ogawa; Peter L Choyke
Journal:  Chem Soc Rev       Date:  2011-05-23       Impact factor: 54.564

4.  Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.

Authors:  D Scott Wilbur; Donald K Hamlin; Ming-Kuan Chyan; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2007-12-12       Impact factor: 4.774

Review 5.  A semiempirical model of tumor pretargeting.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

6.  Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

Authors:  T Saga; R D Neumann; T Heya; J Sato; S Kinuya; N Le; C H Paik; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

7.  Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands.

Authors:  Selvarangan Ponnazhagan; Gandham Mahendra; Sanjay Kumar; John A Thompson; Mark Castillas
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

8.  A novel immunoscintigraphy technique using metabolizable linker with angiotensin II treatment.

Authors:  Y Nakamoto; H Sakahara; T Saga; N Sato; S Zhao; Y Arano; Y Fujioka; H Saji; J Konishi
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.

Authors:  D Marshall; R B Pedley; J A Boden; R Boden; R G Melton; R H Begent
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

10.  Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.

Authors:  D Marshall; R B Pedley; R G Melton; J A Boden; R Boden; R H Begent
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.